Compare ACON & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACON | NDRA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.1M |
| IPO Year | 2022 | 2016 |
| Metric | ACON | NDRA |
|---|---|---|
| Price | $2.29 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 61.1K | 34.1K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.82 | 84.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,730.00 | N/A |
| Revenue This Year | $87.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.62 | N/A |
| 52 Week Low | $1.95 | $2.96 |
| 52 Week High | $12.03 | $9.83 |
| Indicator | ACON | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 63.59 |
| Support Level | $1.95 | $4.35 |
| Resistance Level | $2.50 | $6.08 |
| Average True Range (ATR) | 0.18 | 0.56 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 8.62 | 68.97 |
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.